Quantum-Si Welcomes Jeff Keyes as New CFO: Ready to Take the Company to the Next Level!

Quantum-Si Incorporated (Nasdaq: QSI), The Protein Sequencing Company™, is pleased to announce the appointment of Jeff Keyes as its new Chief Financial Officer, effective May 15, 2023. With more than 25 years of experience in providing transformational financial leadership for both public and private companies, Mr. Keyes is well equipped to guide Quantum-Si through an exciting period of growth.

We are thrilled to announce Jeff’s addition to the Quantum-Si team! He is an executive with immense potential, and he is the perfect fit to help us strategically grow our organization and further commercialize Platinum™. Jeff is a valuable asset to our team, bringing with him a wealth of industry knowledge and operational experience that will be essential in enabling Quantum-Si to reach its long-term goals.

Mr. Keyes is an experienced leader with a successful track record in finance, accounting and mergers and acquisitions. He has held a variety of leadership roles at life science companies and was CFO of both Spinal Elements, Inc., a medical device company, and Custopharm, Inc., a developer of generic sterile injectable pharmaceuticals.

During his time at Custopharm, he drove rapid commercial growth and a successful acquisition by Hikma Pharmaceuticals. Additionally, Mr. Keyes has served on the board of directors of CNS Pharmaceuticals, Inc., a public clinical stage biotech company, since June 2018. He holds a Bachelor of Arts in accounting from Western Washington University and is a certified public accountant.

I’m thrilled to become the CFO of Quantum-Si and join the innovative leadership team to drive growth and optimize shareholder value. Quantum-Si’s cutting-edge protein sequencing technology has the potential to revolutionize our understanding of disease, leading to better diagnostic tools and therapies. I’m excited to be part of this incredible journey and help shape the future of healthcare.

Claudia Drayton has been the Company’s CFO since April 2021, and she will be staying on as a senior advisor until June 30, 2023 to ensure a smooth transition to her successor, Mr. Keyes. We thank Claudia for her invaluable contributions and look forward to her continued guidance as we welcome Mr. Keyes to the team.

Inducement Awards

On May 15, 2023, the Company’s Board of Directors authorized the grant of 1,000,000 time-based stock options, 500,000 performance-based stock options, and 500,000 performance-based stock options to Mr. Keyes upon his commencement of employment, subject to the terms and conditions of their respective stock option agreements.

The Inducement Awards, which offer a ten-year term and an exercise price equal to the fair market value of the Company’s Class A common stock on May 15, 2023, are designed to be inducements material to Mr. Keyes entering into employment with the Company.

The time-based stock options will vest as to 25% on the last day of the calendar quarter containing the one year anniversary of Mr. Keyes’ start date, with the remainder vesting in 36 equal monthly installments at the end of each month thereafter.

The performance-based stock options will vest in full if within one year of Mr. Keyes’ start date the Class A common stock closing price is at least $10.00 (as adjusted) for 20 out of 30 consecutive trading days, and if within three years of his start date the Class A common stock closing price is at least $20.00 (as adjusted) for

About Quantum-Si Incorporated

Quantum-Si is harnessing the power of cutting edge semiconductor technology to revolutionize the field of proteomics. With the ability to sequence single molecules and digitize proteomic research, the Company’s suite of technologies is set to take drug discovery and diagnostics to the next level, transforming what was once thought possible with DNA sequencing.

Leave a Comment